CompletedNot Applicable

Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer

United Kingdom33 participantsStarted 2010-08

Plain-language summary

RATIONALE: Gathering information from patients who have undergone treatment for upper gastrointestinal cancer or gynecological cancer may help doctors learn more about patients' physical and psychosocial rehabilitation needs and plan the best treatment. PURPOSE: This clinical trial is studying the physical and psychosocial rehabilitation needs of patients after diagnosis and treatment of upper gastrointestinal cancer or gynecological cancer.

Who can participate

Age range

18 Years – 120 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of upper gastrointestinal (GI) or gynecological cancer * Must have completed initial treatment for upper GI or gynecological cancer * Received primary treatment within the Royal Marsden NHS Foundation Trust * Will be on a treatment pathway with radical intent or be post-treatment * Reported that they have experienced a physical or psychosocial need resulting from the disease or its treatment PATIENT CHARACTERISTICS: * Able to attend the specialist center for a focus group session * Willing and able to articulate their experiences in English * Not eligible for or receiving palliative or end-of-life care PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Patients' perspective of their physical and psychosocial rehabilitation needs following their diagnosis and treatment

Patients' experiences of the physical and social impact of cancer in the treatment and post-treatment phase

Patients' met and un-met needs

Patients' opinion of how to manage any of the issues that arise

Trial details

NCT IDNCT01216813

SponsorRoyal Marsden NHS Foundation Trust

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2010-10

View on ClinicalTrials.gov More Adenocarcinoma of the Gastroesophageal Junction trials